Buscar
Congreso SOLACI
HomeInternational CongressesESC 2025

ESC 2025

Ver Categoría

ESC 2025

Watch again – New Guidelines for the Management of Heart Valve Disease: Implications for Interventional Cardiology

You can now watch our webinar on “New Guidelines for the Management of Heart Valve Disease: Implications...
solaci -
Ver más
ESC 2025

ESC 2025: Results of the NEO-MINDSET study — exclusive presentation and analysis with Dr. Pedro Lemos

Following the presentation of the NEO-MINDSET study in the Late Breaking Clinical Trials sessions at the European...
solaci -
Ver más
Antithrombotic Anticoagulants

ESC 2025 | HI-PRO: Extended Apixaban for Recurrence Prevention in Provoked DVT/PE

Patients with provoked venous thromboembolism (VTE) usually discontinue anticoagulation after 3 to 6 months. However, in the...
Dr. Omar Tupayachi -
Ver más
Acute coronary syndromes

ESC 2025 | BETAMI-DANBLOCK: Randomized Discontinuation of Beta-Blockers after MI

The routine use of beta-blockers after acute myocardial infarction (AMI) has been a historical recommendation based on...
Dr. Omar Tupayachi -
Ver más
Structural Heart Disease

ESC 2025 | DOUBLE-CHOICE: Anesthesia Strategies and Self-Expanding Valves in TAVI

TAVI has become the predominant treatment for severe aortic stenosis. The DOUBLE-CHOICE trial analyzed two key aspects:...
Dr. Omar Tupayachi -
Ver más
Coronary disease

ESC 2025 | DIGIT-HF: Digitoxin in Heart Failure with Reduced Ejection Fraction

Heart failure with reduced ejection fraction (HFrEF) continues to represent a clinical challenge despite advances in pharmacological...
Dr. Omar Tupayachi -
Ver más
Coronary Disease

ESC 2025 | AMALFI: Remote Monitoring for Atrial Fibrillation Detection

Since atrial fibrillation (AF) may be asymptomatic and remain undiagnosed, the AMALFI study aimed to assess whether...
Dr. Juan Manuel Pérez -
Ver más
Chronic Ischemic cardiopathy

ESC 2025 | DANCAVAS 2: Cardiovascular Screening in Men Aged 60 to 64 Years

Cardiovascular diseases account for 31% of deaths in men under 70 years of age. In the DANCAVAS...
Dr. Juan Manuel Pérez -
Ver más

SOLACI es la organización de referencia del intervencionismo cardiovascular latinoamericano.

Últimas Noticias

Tricuspid Regurgitation, TriBicaval Registry

Dr. Carlos Fava - 0
Tricuspid regurgitation (TR) is a condition whose prevalence is expected to increase in the coming years. Surgery presents important challenges and is associated with...

IVI-Guided PCI vs Coronary Artery Bypass Surgery in Left Main Coronary or Multivessel Disease

Dr. Andrés Rodríguez - 0
Several randomized clinical trials have demonstrated the superiority of coronary artery bypass grafting (CABG) over percutaneous coronary intervention (PCI) in patients with left main...

Edge-To-Edge Treatment with PASCAL: Are There Sex-Specific Differences?

Dr. Carlos Fava - 0
Mitral regurgitation (MR) is a common valve disease associated with heart failure, hospitalizations, and mortality.  In women, it is often overlooked and some analyses have...

Noticias Institucionales

Watch again – New Guidelines for the Management of Heart Valve Disease: Implications for Interventional Cardiology

solaci - 0
You can now watch our webinar on “New Guidelines for the Management of Heart Valve Disease: Implications for Interventional Cardiology”, held via Zoom on...

ESC 2025: Results of the NEO-MINDSET study — exclusive presentation and analysis with Dr. Pedro Lemos

solaci - 0
Following the presentation of the NEO-MINDSET study in the Late Breaking Clinical Trials sessions at the European Society of Cardiology Congress (ESC 2025), Dr....

SOLACI Webinar – New Guidelines for the Management of Valvular Heart Disease: Implications for Interventional Cardiology

solaci - 0
A new SOLACI virtual scientific event is coming up as part of the scientific coverage of the ESC 2025 Congress. This session will focus on...

Accesos

Adolfo Alsina 2653 · Piso 2H · CABA · Buenos Aires · Argentina · (5411) 4954 7173 · info@solaci.org · solaci.org · Términos de uso -Políticas de privacidad